SARAH FENDER: Open Payments
NPI 1699421370 · WEST COLUMBIA, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,672 in 62 payments from 23 companies in 2025. Trend: 2023 $78 · 2024 $1,502 · 2025 $1,672
Food & beverage: $1,672
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $474 |
| MERZ NORTH AMERICA, INC. | 1 | $153 |
| AstraZeneca Pharmaceuticals LP | 3 | $148 |
| Novartis Pharmaceuticals Corporation | 3 | $88 |
| ACADIA Pharmaceuticals Inc | 3 | $79 |
| UCB, Inc. | 3 | $76 |
| TG Therapeutics, Inc. | 3 | $70 |
| EMD Serono, Inc. | 2 | $64 |
| Eisai Inc. | 2 | $56 |
| Neurocrine BioSciences, Inc. | 2 | $56 |
Products named: QULIPTA, Xeomin, UBRELVY, WAINUA, KESIMPTA, NUPLAZID, BRIUMVI, BOTOX.
Industry payments across SC — which companies pay providers there.
